Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSymphony Env. Regulatory News (SYM)

Share Price Information for Symphony Env. (SYM)

Share Price is delayed by 15 minutes
Get Live Data
6.75    0.00 (0.00%)
Bid:
6.00
Ask:
7.50
Spread: 1.50 (25.00%)
Market Cap: £15.95m
SYM Live PriceLast checked at - London Stock Exchange

Intraday Symphony Env. Share Chart

HSAC report

7 Apr 2026 07:00

RNS Number : 4271Z
Symphony Environmental Tech. PLC
07 April 2026
 

 

This is a Reach (i.e. non-regulatory) announcement and the information contained is not considered to be material or to have a significant impact on management's expectations of the Company's performance.

Symphony Environmental Technologies Plc

("Symphony" or the "Company")

Analysis of UK Government Report Confirms d2w® Biodegradable Plastic Is Proven, Tested and Safe

Symphony Environmental Technologies Plc ("Symphony" or "the Company") a global leader in "smarter, safer, and sustainable" plastic and rubber technologies, is delighted to announce that a comprehensive scientific analysis confirms that oxo‑biodegradable plastic technology is a proven, well‑established solution, supported by decades of independent testing and real‑world use.

The analysis demonstrates that this technology is not experimental, novel or untested, but is based on over 50 years of polymer science, more than 30 years of global commercial use, and extensive testing by leading scientists and internationally accredited laboratories.

The evidence shows that d2w® plastics are specifically designed to degrade safely in the open environment and then biodegrade without leaving behind persistent microplastics, while remaining compatible with existing recycling systems where collection occurs.

The Biodegradable Plastics Association (BPA) has today published its response https://www.biodeg.org/wp-content/uploads/2026/03/BPA-RESPONSE-31.3.26.pdf to the UK Government's 2025 HSAC Report This BPA paper demonstrates conclusively that there is no technical, scientific, or safety‑based reason to prohibit or discourage the use of oxo‑biodegradable polyethylene (PE) and polypropylene (PP), provided they are correctly manufactured, and assessed using the appropriate international standards.

First, the paper establishes that oxo‑biodegradable plastic is not an experimental or unproven technology. It has been in continuous scientific development for over fifty years, and has been in commercial use for 20 years. It was invented by leading polymer scientists, and is supported by a coherent and well‑understood mechanism: - controlled oxidative chain scission followed by biological assimilation.

It is fundamentally different from composting and mere physical fragmentation, and it does not leave microplastics. This two‑stage process is recognised and understood in the international technical literature and Standards, and there is no credible dispute in polymer science that oxidation reduces molecular weight and that sufficiently oxidised polyolefins are biodegradable. This has been demonstrated in the real world, notably by the Oxomar project.

Second, the paper shows that the correct technical benchmark already exists. ASTM D6954 (and aligned national standards such as BS 8472) was specifically written to assess plastics intended to degrade and then biodegrade in the open environment. These standards define what must be measured, how it must be measured, and what constitutes pass or fail for degradation, biodegradation, and environmental safety. The existence and long‑standing use of these standards means there is no technical gap requiring new methodologies, speculative testing regimes, or ad‑hoc academic proxies.

Third, the paper demonstrates that independent, ISO 17025‑accredited testing has already proven performance. The Intertek test reports cited show high levels of biodegradation of oxo‑biodegradable PE and PP, compliance with ecotoxicity requirements, and-critically-the absence of persistent microplastics. Molecular‑weight measurements confirm that any residual particles no longer behave as plastics. From a regulatory and technical standpoint, this directly addresses the principal concerns typically raised: persistence, toxicity, and microplastic formation.

Fourth, the paper shows that claims of technical failure are driven by inappropriate test protocols not by deficiencies in the technology. See https://www.biodeg.org/wp-content/uploads/2026/03/BPA-Dossier-with-links-10-2-26-optimised-V13-31-Mar-26.pdf Many academic papers which have passed peer-review, either test the wrong materials, fail to characterise samples, use incorrect standards (e.g. composting standards), terminate tests prematurely, or expose materials to conditions for which they were not designed (such as burial or submersion). The paper demonstrates that such studies cannot be used to draw valid conclusions about the performance of properly made oxo‑biodegradable plastics.

Fifth, the paper addresses geographical variability directly and shows that variation in degradation rate is not technical failure. Like all chemical and biological processes, oxo‑biodegradation proceeds more slowly in cooler or lower‑UV conditions, but there is no evidence that the process fails, stops, or reverses. This behaviour is entirely consistent with established kinetics.

No regulatory principle requires uniform degradation speed across climates, only predictable and demonstrable performance relative to conventional plastics-which oxo‑biodegradable materials are intended to replace.

Sixth, the paper confirms that oxo‑biodegradable plastic is compatible with recycling, unlike some alternative materials that are nevertheless permitted on the market. There is therefore no technical incompatibility with circular‑economy objectives for collected material, while still providing a clear environmental advantage for plastic that inevitably escapes collection.

Taken together, the evidence shows that oxo‑biodegradable plastic such as d2w®:

· functions as designed;

· is supported by established polymer science and long user;

· is testable and verifiable using recognised standards;

· has been independently proven to biodegrade without creating persistent microplastics or ecotoxicity; and

· performs better than conventional plastic if it gets into the open environment, which is the only context in which its designed function is relevant.

Accordingly, this paper demonstrates that there is no technical justification for prohibition, restriction, or regulatory exclusion of oxo‑biodegradable plastics.

 

For further information, please contact:

Symphony Environmental Technologies Plc

Tel: +44 (0)20 8207 5900

Website: https://www.symphonyenvironmental.com

 

NOTES TO EDITORS

Symphony also supplies a range of plastic technologies under its d2p (designed to protect) brand www.d2p.net to provide protection against insects, viruses, bacteria, fungi, rodents, odours, and fire. It has also introduced a new product under its NbR brand https://www.symphonyenvironmental.com/natural-biodegradable-resin/ to reduce the amount of fossil-derived material in plastic products.

Symphony has a diverse and growing customer-base and has established itself as an international business with over 70 distributors around the world. Products made with Symphony's plastic technologies are now available in nearly 100 countries and in many different product applications. Symphony itself is certified according to ISO9001 and ISO14001.

Symphony participates in the Committee work of the British Standards Institute (BSI), the American Standards Organisation (ASTM), the European Standards Organisation (CEN), and the International Standards Organisation (ISO).

Further information on the Group can be found at www.symphonyenvironmental.com 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUNURRNUUSRUR
Date   Source Headline
25th Mar 20243:02 pmRNSReplacement - Subscription and Notice of GM
22nd Mar 20247:01 amRNSPrimaryBid Offer
22nd Mar 20247:00 amRNSSubscription, PrimaryBid Offer and Notice of GM
14th Mar 20247:00 amRNSExtension to Convertible Loan Agreements
13th Mar 20247:00 amRNSUS Environmental Protection Agency positive report
9th Feb 20247:59 amRNSEU Judgment – Company Response
31st Jan 20249:48 amRNSEU Court Judgement
18th Jan 20247:00 amRNSTrading Update and EU Case
8th Jan 20247:00 amRNSGrant of options and PDMR dealing
2nd Jan 20247:00 amRNSDirector appointment & grant of options
28th Dec 20237:00 amRNSOptions amendments
18th Oct 20232:10 pmRNS£1.0m convertible loan agreement
29th Sep 20237:00 amRNSInterim Results
26th Sep 20237:00 amRNSYemen Enforces Oxo-Biodegradable Plastic Law
11th Aug 20237:00 amRNSDirectorate Change
1st Aug 20237:00 amRNSPre-close Trading Update
4th Jul 20237:00 amRNSDirectorate Change
29th Jun 20231:46 pmRNSResult of AGM
29th Jun 20237:00 amRNSAGM Statement
7th Jun 20238:34 amRNSPosting of Annual Report & Accounts & AGM Notice
30th May 20237:00 amRNSPreliminary Results
21st Mar 20237:00 amRNSEU court hearing
13th Mar 20233:40 pmRNSConvertible loan agreement & revenue update
9th Mar 20237:00 amRNSd2w BioBottles supply agreement with TricorBraun
23rd Dec 20227:00 amRNSTrading update
31st Oct 20227:00 amRNSAttendance at world’s leading plastics trade fair
28th Oct 20222:51 pmRNSDirector/PDMR Shareholdings – Option amendments
29th Sep 20229:00 amRNSInvestor Presentation
29th Sep 20227:01 amRNSSymphony India operations update
29th Sep 20227:00 amRNSInterim results for the 6 m/e 30 June 2022
9th Aug 20227:00 amRNSMexican Technical Standard Validating d2w
8th Aug 20227:00 amRNSAgreement for Middle East manufacturing
1st Aug 20227:01 amRNSEquity subscription and grant of warrants
1st Aug 20227:00 amRNSTrading Update
7th Jul 20227:00 amRNSd2p Anti-Insect Sales
29th Jun 20222:00 pmRNSResult of AGM
29th Jun 20227:00 amRNSAGM Statement
28th Jun 20227:00 amRNSd2p Supply Agreement with Grupo Bimbo
27th Jun 20227:00 amRNSPeru legal action outcome
7th Jun 20227:00 amRNSPosting of Annual Report and Notice of AGM
18th May 20227:00 amRNSAppointment of Executive Director
4th May 20227:00 amRNSGrant of Options
20th Apr 20227:00 amRNSSymphony India Sustainability Award
30th Mar 20227:00 amRNSPreliminary results
24th Feb 20223:49 pmRNSExtension of options
23rd Feb 20227:00 amRNSNew US Supply Contract
17th Dec 20212:09 pmRNSTrading and business update
29th Nov 20217:00 amRNSPositive DEFRA consultation
19th Nov 20212:54 pmRNSDirector/PDMR Shareholding - options amendment
19th Nov 20212:11 pmRNSDirector/PDMR Shareholding - option amendments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.